In a report released today, John Ransom from Raymond James maintained a Buy rating on UnitedHealth (NYSE: UNH), with a price target of $304. The company’s shares closed on Friday at $266.67, close to its 52-week high of $271.16.
According to TipRanks.com, Ransom is a 5-star analyst with an average return of 13.6% and a 67.2% success rate. Ransom covers the Services sector, focusing on stocks such as Walgreens Boots Alliance, Addus Homecare Corp, and LifePoint Health.
Currently, the analyst consensus on UnitedHealth is a Strong Buy with an average price target of $289.88, an 8.7% upside from current levels. In a report issued on September 17, Cowen & Co. also initiated coverage with a Buy rating on the stock with a $308 price target.
.
See today’s analyst top recommended stocks >>
Based on UnitedHealth’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $56.09 billion and net profit of $2.92 billion. In comparison, last year the company earned revenue of $50.05 billion and had a net profit of $2.28 billion.
Based on the recent corporate insider activity of 186 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Michele Hooper, a Director at UNH sold 5,000 shares for a total of $1,324,300.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
